Stock VTGN VISTAGEN THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Revisions Vistagen Therapeutics, Inc.

Equities

VTGN

US92840H4002

Real-time Estimate Cboe BZX
Other stock markets
 11:10:57 2024-04-30 am EDT 		5-day change 1st Jan Change
4.67 USD -2.10% Intraday chart for Vistagen Therapeutics, Inc. -2.28% -8.17%
Apr. 25 Vistagen Announces Positive Results from Phase 2A Pilot Study of Ph15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue CI
Apr. 01 Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2 CI

Turnover - Change in analysts' estimates

Earnings Per Share (EPS) - Change in analysts' estimates

EBIT - Change in analysts' estimates

Cash or Net Debt - Change in analysts' estimates

Turnover

Earnings Per Share (EPS)

EBIT

Cash or Net Debt

  1. Stock Market
  2. Equities
  3. VTGN Stock
  4. Revisions Vistagen Therapeutics, Inc.